title: Evaluation of multiple serum markers in advanced melanoma.
abstract: The aim of this retrospective study was to analyse in advanced melanoma the potential tumor markers S-100B, melanoma inhibiting activity protein (MIA) and YKL-40 compared to LDH. Serum levels of S-100B, MIA, LDH and YKL-40 were measured in 110 patients with advanced melanoma (36 in stage IIIB/C and 74 in stage IV), in 66 disease-free patients and in 65 healthy controls. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. The combination of S-100B plus MIA had the best diagnostic sensitivity, and the addition of LDH did not further increase this sensitivity. MIA was an independent prognostic factor of overall survival. Patients with both S-100B and MIA elevated had a significant shorter survival than those with both S-100B and MIA under the cut-off. YKL-40 levels did not differentiate patients with advanced melanoma from controls. We concluded that the combination of MIA plus S-100B showed a better prognostic value in advanced melanoma compared to LDH.
authors.affiliation: Laboratory of Biochemistry, University Clinic of Navarra, Avd. Pio XII 36, Pamplona, 31008, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Díaz-Lagares
authors.forename: Estíbaliz
authors.initials: E
authors.lastname: Alegre
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Arroyo
authors.forename: María
authors.initials: M
authors.lastname: González-Cao
authors.forename: Maria E
authors.initials: ME
authors.lastname: Zudaire
authors.forename: Santiago
authors.initials: S
authors.lastname: Viteri
authors.forename: Salvador
authors.initials: S
authors.lastname: Martín-Algarra
authors.forename: Alvaro
authors.initials: A
authors.lastname: González
mesh_terms: D054392:Adipokines / Q000097:blood; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D000071451:Chitinase-3-Like Protein 1; D004797:Enzyme-Linked Immunosorbent Assay; D016326:Extracellular Matrix Proteins / Q000097:blood; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007770:L-Lactate Dehydrogenase / Q000097:blood; D037102:Lectins / Q000097:blood; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000175:diagnosis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood; D009367:Neoplasm Staging; D009414:Nerve Growth Factors / Q000097:blood; D011379:Prognosis; D021122:Protein Subunits / Q000097:blood; D012372:ROC Curve; D012189:Retrospective Studies; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood; D012867:Skin / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000097:blood* / Q000175:diagnosis
chemical_list: D054392:Adipokines; D014408:Biomarkers, Tumor; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D016326:Extracellular Matrix Proteins; D037102:Lectins; C090059:MIA protein, human; D009363:Neoplasm Proteins; D009414:Nerve Growth Factors; D021122:Protein Subunits; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D007770:L-Lactate Dehydrogenase